ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test

被引：0

作者：

Freitas, H. C. ^{[1
]}

Park, K. ^{[2
]}

Kim, D-W. ^{[3
]}

Tiseo, M. ^{[4
]}

Hochmair, M. J. ^{[5
,6
]}

Chang, G-C. ^{[7
]}

Shi, Y-K. ^{[8
,9
]}

Moran, T. ^{[10
]}

Chen, Y. ^{[11
]}

Laskin, J. ^{[12
]}

Solomon, B. ^{[13
]}

Miranda, M. ^{[14
]}

Rigas, J. ^{[15
]}

Cheema, P. K. ^{[16
]}

Kim, S-W. ^{[17
]}

机构：

[1] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Heamatol Oncol,Med, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Dept Internal Med, Hematooncol, Seoul, South Korea

[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[5] Otto Wagner Hosp, Dept Resp & Crit Care Med, Resp Oncol Unit, Vienna, Austria

[6] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD, Vienna, Austria

[7] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan

[8] Chinese Acad Med Sci, Natl Canc Ctr, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Beijing, Peoples R China

[9] Peking Union Med Coll, Beijing, Peoples R China

[10] ICO Badalona Hosp Germans Trias & Pujol, Med Oncol Serv, Barcelona, Spain

[11] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan

[12] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada

[13] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[14] AstraZeneca, Biometr & Informat Sci, Cambridge, England

[15] AstraZeneca, GMA Oncol TA, Gaithersburg, MD USA

[16] Univ Toronto, William Osler Hlth Syst, Med Oncol, Brampton, ON, Canada

[17] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

466O

引用

页码：149 / 149

页数：1

共 50 条

[21] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
Yang, Zhengquan
Li, Jialu
Hu, Yujie
Chen, Meihua
Peng, Danli
Zong, Dan
Shang, Qingjuan
Tao, Lianqin
Zhao, Yanling
Ni, Yiyun
Ye, Jinyan
Xie, Yupeng
Yang, Li
Lin, Quan
Cai, Chang
Xu, Ning
Huang, Xiaoping
Dong, Xiaoting
Zhou, Zhonghui
Yu, Yali
Shangguan, Zongxiao
Xu, Yangyang
Ying, Weiping
Weng, Meiling
Yuan, Zuguo
Dong, Zhijun
Li, Jifa
Zheng, Zhe
Pan, Jiongwei
Liu, Lu
Ye, Junhui
Zhang, Zhan
Li, Wenfeng
Zhu, Junfei
Jin, Shengnan
Li, Yuping
Ding, Chunming
TARGETED ONCOLOGY, 2019, 14 (06) : 719 - 728
[22] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Luo, Yung-Hung
Liu, Han
Wampfler, Jason A.
Tazelaar, Henry D.
Li, Yalun
Peikert, Tobias
Liu, Dan
Leventakos, Konstantinos
Chen, Yuh-Min
Yang, Yanan
Chiou, Shih-Hwa
Yang, Ping
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2099 - 2114
[23] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
Zhengquan Yang
Jialu Li
Yujie Hu
Meihua Chen
Danli Peng
Dan Zong
Qingjuan Shang
Lianqin Tao
Yanling Zhao
Yiyun Ni
Jinyan Ye
Yupeng Xie
Li Yang
Quan Lin
Chang Cai
Ning Xu
Xiaoping Huang
Xiaoting Dong
Zhonghui Zhou
Yali Yu
Zongxiao Shangguan
Yangyang Xu
Weiping Ying
Meiling Weng
Zuguo Yuan
Zhijun Dong
Jifa Li
Zhe Zheng
Jiongwei Pan
Lu Liu
Junhui Ye
Zhan Zhang
Wenfeng Li
Junfei Zhu
Shengnan Jin
Yuping Li
Chunming Ding
Targeted Oncology, 2019, 14 : 719 - 728
[24] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Yung-Hung Luo
Han Liu
Jason A. Wampfler
Henry D. Tazelaar
Yalun Li
Tobias Peikert
Dan Liu
Konstantinos Leventakos
Yuh-Min Chen
Yanan Yang
Shih-Hwa Chiou
Ping Yang
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
[25] Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
Chang, G.
Shih, J.
Chao, H.
Yang, C.
Lin, C.
Hung, J.
Hsiao, S.
Wang, C.
Chian, C.
Hsia, T.
Yu, C.
Chen, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S679 - S679
[26] Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M
Masuhiro, Kentaro
Shiroyama, Takayuki
Suzuki, Hidekazu
Takata, So
Nasu, Shingo
Takada, Hiromune
Morita, Satomu
Tanaka, Ayako
Morishita, Naoko
Okamoto, Norio
Hirashima, Tomonori
ANTICANCER RESEARCH, 2018, 38 (06) : 3567 - 3571
[27] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Zhang, X.
Wu, Y-L.
Chen, Y.
Zhang, H.
Wu, G.
Lu, Y.
Liang, Z.
Hu, Y.
Cheng, Y.
Wang, J.
Ying, J.
Liu, W.
Liang, Z.
ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
[28] EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
Hochmair, Maximilian J.
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Arns, Madeleine
Errhalt, Peter
Absenger, Gudrun
Koller-Herzog, Ursula
Setinek, Ulrike
Haslbauer, Ferdinand
Korger, Mark A.
Patocka, Kurt
Kolb, Rainer
Burghuber, Otto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[29] EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
Hochmair, Maximilian
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Madeleine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1254
[30] Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation
Yoshimura, Naruo
Takahashi, Hidenori
Kurosawa, Emiko
Tanaka, Akiko
Ebina, Masahito
Ohrui, Takashi
ANNALS OF ONCOLOGY, 2019, 30 : 139 - 139

← 1 2 3 4 5 →